ADA 2020

Highlights from the 80th Annual American Diabetes Association (ADA) Virtual Scientific Sessions.

Real-World Data Find Few Differences in Cardiovascular Outcomes between SGLT2 Inhibitors and GLP1 Agonists

Presenter: Insiya Poonawalla, MD

Real-world data show higher treatment persistence with the sodium-glucose contransporter-2 (SGLT2) inhibitors compared with glucagon-like peptide-1 (GLP1 agonists) but equivalent cardiovascular outcomes between the two classes, with the exception of development of heart failure, which favors the SGLT2 inhibitors.

Diabetes-Related Stress and A1C Improved with Visits to Virtual Diabetes Clinic

Presenters: William H. Polonsky, PhD, and Ronald F. Dixon, MD

Participation in a virtual diabetes clinic that incorporates a telehealth program to support people with type 2 diabetes mellitus (T2DM) leads to a reduction in diabetes-related distress and an improvement in hemoglobin A1c (A1c) level. Users of real-time continuous glucose monitoring (rtCGM) had a significantly greater reduction in distress than nonusers

Best: Bexagliflozin Led to Significant Reductions in HBA1C and Cardiovascular Risk Factors in Patients with Type 2 Diabetes

Presenter: John J.V. McMurray, MD

The SGLT2 inhibitor bexagliflozin reduced HbA1c in patients at high risk of cardiovascular (CV) events and had beneficial effects on weight and blood pressure in the placebo-controlled multinational BEST trial. Bexagliflozin also proved to be noninferior to placebo in a prespecified analysis of CV safety, said John J.V. McMurray, MD, professor of medical cardiology and deputy director, BHF Cardiovascular Research Center, University of Glasgow, Scotland, UK.

DPPOS Shows Long-Term Diabetes Prevention with Lifestyle and Metformin Intervention; Preventing Diabetes Lowers Risk of Vascular Complications

Presenters: David M. Nathan, MD; Mark Molitch, MD; Ronald B. Goldberg, MD; Brandy Heckman-Stoddard, PhD, MD; and Jose A. Luchsinger, MD, MPH

Long-term follow-up of 2,779 people enrolled in the Diabetes Prevention Program Outcomes Study (DPPOS) indicates a continued significant reduction in the participants’ risk of developing type 2 diabetes mellitus (T2DM) through intensive lifestyle intervention or use of metformin.

Ketoacidosis Rate Reduced Dramatically after Initiation of Sensor-Based Glucose Monitoring

Presenter: Ronan Roussel, MD, PhD

A dramatic reduction in the rate of ketoacidosis-related hospitalizations occurred in France in patients with type 1 or type 2 diabetes who started using a sensor-based glucose monitoring system (FreeStyle Libre), especially among those patients who previously reported a very low rate of self-monitoring of blood glucose.